Researchers report promising results using the drug in combination with docetaxel and prednisone. STOCKHOLM—Sunitinib used in tandem with docetaxel and prednisone appears to be safe and well tolerated ...

Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC) No significant financial relationships ...

Background: Hormone refractory prostate cancer (HRPC) has been a therapeutic challenge due to limited and temporary response to treatment. A prior phase I trial with this allogeneic HLA class I ...

Recent studies have evaluated the use of NHAs as initial (neoadjuvant) therapy for HRPC, with the goal of shrinking the tumor before prostate cancer surgery (radical prostatectomy, or RP). A clinical ...

The Harvard-Radcliffe Policy Committee is formulating plans for a new system of student representation on committees to revamp college curricula. At an HRPC meeting last week, a tentative scheme was ...

Macclesfield, UK, 25 September 2007. New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), ...

ORLANDO—A new therapeutic vaccine called Prostvac-VF may prolong survival in men with metastatic hormone-refractory prostate cancer (HRPC), according to new data presented here at the 45 th Annual ...

June 14, 2007 — Radioisotope radium-223 has shown promise as a new treatment for patients with bone metastases resulting from hormone-refractory prostate cancer (HRPC). The results of a small study ...

WILMINGTON, Del., Sept. 25 -- The results from the randomized, double-blind, placebo-controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 -- a specific endothelin A (ETA) receptor ...

Clinical efficacy of current therapies for hepatocellular carcinoma (HCC) treatment is limited. Indole-3-acetic acid (IAA) is non-toxic for mammalian cells. Oxidative decarboxylation of IAA by ...